3 Pain and Anti-Malarial Brand Owner, Contract Formulations Maker and Branded Generics Exporter Stocks With a Strong Future Roadmap: Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals
- October 26, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals: ROE of 11.6% to 14.2% and FY22 to FY26 revenue CAGR of 9.9% to 19.5%. Prices as of 23 Oct 2026.
Quick Answer
The three formulation and branded generic pharma stocks to watch are Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals. Their return on equity ranges from 11.6% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 19.5%. Ipca Laboratories has the highest return on equity at 14.2%, while Innova Captab has the fastest revenue growth at 19.5% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Formulation and branded generic pharma stocks bring together companies with a visible plan for the years ahead. Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals cover a pain and anti-malarial brand owner, a contract formulations maker and a branded generics exporter.
This list covers three formulation and branded generic pharma stocks with complete current figures: Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Formulation and Branded Generic Pharma Stocks?
Formulation and branded generic pharma stocks are listed drug makers that make formulations, branded generics and active ingredients for domestic and emerging market customers. Their earnings depend on brand demand, contract orders and export approvals.
Formulation and Branded Generic Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Ipca Laboratories | 1,953.3 | 46,050 | 33.5 | 36.0 | 14.2 | 0.10 |
| Innova Captab | 987.3 | 5,736 | 37.2 | 36.0 | 12.9 | 0.32 |
| Lincoln Pharmaceuticals | 512.7 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
On valuation, Ipca Laboratories and Lincoln Pharmaceuticals trade at a P/E below the industry P/E, while Innova Captab trades above it, which reflects the growth the market already expects. Readers comparing formulation and branded generic pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Formulation and Branded Generic Pharma Stocks Have a Strong Roadmap in India?
Formulation and branded generic pharma stocks have a strong roadmap in India because outsourcing by larger drug companies, growing rural healthcare and rising exports to emerging markets keep widening the opportunity.
- Contract manufacturing. Larger companies outsource formulation work.
- Emerging markets. Exports to Africa and Asia add steady orders.
- Brand depth. Established pain and infection brands retain loyal users.
Why Ipca Laboratories Features Among These Formulation and Branded Generic Pharma Stocks
Among the formulation and branded generic pharma stocks on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.
Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.
Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.
Why Innova Captab Features Among These Formulation and Branded Generic Pharma Stocks
Among the contract drug maker shares on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.
Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%.
In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.
Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.
Why Lincoln Pharmaceuticals Features Among These Formulation and Branded Generic Pharma Stocks
Among the three companies on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%.
Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Ipca Laboratories vs Innova Captab vs Lincoln Pharmaceuticals on Key Financials
The table below sets the three formulation and branded generic pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Ipca Laboratories | 5,896 | 9,821 | 13.6% | 1,191 | 12.1% |
| Innova Captab | 803 | 1,637 | 19.5% | 141 | 8.6% |
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
Ipca Laboratories posts the highest return on equity in this group at 14.2%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with formulation and branded generic pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Ipca Laboratories | 2,342 | 2,813 | 20.2% |
| Innova Captab | 356 | 473 | 32.8% |
| Lincoln Pharmaceuticals | 169 | 202 | 19.0% |
Key Risks to Check Before Investing in Formulation and Branded Generic Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these formulation and branded generic pharma stocks, the main points are: Long-term contract drug maker shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices can fall.
- Input costs. Raw material prices influence margins.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter formulation and branded generic pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Formulation and Branded Generic Pharma Stocks
Formulation and branded generic pharma stocks suit investors who prefer to study business strength before price moves. Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals each have a clear plan to grow. Based on the 23 October 2026 close, Ipca Laboratories trades at Rs 1,953.3, Innova Captab at Rs 987.3 and Lincoln Pharmaceuticals at Rs 512.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these formulation and branded generic pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track formulation and branded generic pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are formulation and branded generic pharma stocks?
Ans. Formulation and branded generic pharma stocks are listed drug makers that make formulations, branded generics and active ingredients for domestic and emerging market customers. Their earnings depend on brand demand, contract orders and export approvals. This list looks at three of them, Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which formulation and branded generic pharma stocks are covered in this list?
Ans. This list covers Ipca Laboratories, Innova Captab and Lincoln Pharmaceuticals. Based on the 23 October 2026 close, Ipca Laboratories traded at Rs 1,953.3, Innova Captab at Rs 987.3 and Lincoln Pharmaceuticals at Rs 512.7. Their return on equity ranges from 11.6% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 19.5%.
Why do formulation and branded generic pharma stocks have a strong future roadmap in India?
Ans. Formulation and branded generic pharma stocks have a strong roadmap in India because outsourcing by larger drug companies, growing rural healthcare and rising exports to emerging markets keep widening the opportunity. The main drivers are as follows. Contract manufacturing. Larger companies outsource formulation work. Emerging markets. Exports to Africa and Asia add steady orders. Brand depth. Established pain and infection brands retain loyal users. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Ipca Laboratories performed financially?
Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
How has Innova Captab performed financially?
Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What risks should investors check before buying formulation and branded generic pharma stocks?
Ans. Investors should check a few risks before buying formulation and branded generic pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices can fall. Input costs. Raw material prices influence margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of formulation and branded generic pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.